Document resource
Bronchopulmonary dysplasia (BPD) is the most common morbidity of preterm birth, affecting up to 50 000 infants each year in the USA.1 Fine particulate matter <2.5 µm in diameter (PM2.5) is a measure of air pollution, and our team recently reported that among infants diagnosed with grade 1 BPD (≤2 L/min nasal cannula at 36 weeks postmenstrual age) and discharged from a Philadelphia hospital system, each 1 μg/m3 increment of PM2.5 was associated with 65% higher odds of medically attended acute respiratory illness in the first year after neonatal intensive care unit (NICU) discharge.2 The Environmental Protection Agency recently lowered the level of the health-based standard of annual average PM2.5 exposure from 12 to 9 μg/m3. While a concentration-response association has been identified of PM2.5 with mortality, chronic obstructive pulmonary disease and asthma medication use in adults, the policy-relevant impact of reducing PM2.5 exposure among infants with BPD remains unknown.3–5